OCA
CABA icon

Octagon Capital Advisors’s Cabaletta Bio CABA Stock Holding History

Octagon Capital Advisors’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-52,000
Closed -$887K – 50
2024
Q1 		$887K Buy
+52,000
New +$1.12M 0.11% 57

Other funds holding CABA

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Octagon Capital Advisors's CABA Position: Q2 2024 in Review

Octagon Capital Advisors sold out of Cabaletta Bio (CABA) in Q2 2024, closing a stake of 52,000 shares — an estimated $887K sold.

Octagon Capital Advisors first reported a position in CABA in Q1 2024 and held it in 1 quarter. The position peaked at $887K in Q1 2024. 142 funds tracked by Wall St. Rank hold CABA as of Q2 2024.

  • Octagon Capital Advisors reported no remaining Cabaletta Bio position as of Q2 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 52,000 Cabaletta Bio shares in Q2 2024, an estimated $887K.
  • Octagon Capital Advisors first reported a position in Cabaletta Bio in Q1 2024 and held it in 1 quarter.
  • Octagon Capital Advisors's Cabaletta Bio position peaked at $887K in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2024.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.